Constellation Pharmaceuticals (NASDAQ: CNST) is one of 548 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Constellation Pharmaceuticals to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and target prices for Constellation Pharmaceuticals and its competitors, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Constellation Pharmaceuticals 0 0 5 0 3.00
Constellation Pharmaceuticals Competitors 4553 13028 27681 994 2.54

Constellation Pharmaceuticals presently has a consensus target price of $17.80, suggesting a potential upside of 44.60%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.67%. Given Constellation Pharmaceuticals’ competitors higher possible upside, analysts clearly believe Constellation Pharmaceuticals has less favorable growth aspects than its competitors.

Earnings and Valuation

This table compares Constellation Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Constellation Pharmaceuticals N/A -$59.92 million -2.46
Constellation Pharmaceuticals Competitors $2.15 billion $228.73 million -3.55

Constellation Pharmaceuticals’ competitors have higher revenue and earnings than Constellation Pharmaceuticals. Constellation Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.


This table compares Constellation Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Constellation Pharmaceuticals N/A N/A N/A
Constellation Pharmaceuticals Competitors -1,760.46% -120.17% -28.09%

Institutional and Insider Ownership

60.0% of Constellation Pharmaceuticals shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.


Constellation Pharmaceuticals beats its competitors on 7 of the 12 factors compared.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include CPI-0610 that is in Phase II clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib; and CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors. It is also developing CPI-0209, which is in preclinical trials for the treatment of solid tumors. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was founded in 2008 and is based in Cambridge, Massachusetts.

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with's FREE daily email newsletter.